Nitric oxide-independent inhibitory effects of L-arginine analog NG-monomethy-L-arginine on the generation of interleukin-2 activated cytotoxic activity in humans

Clinical Nutrition

Volumn 15, Issue 1, 1996, Pages 16-20

  Juretic A ^a   Spagnoli, G C ^a   Horig H ^a   Gross, T ^a   Gallati, H ^b   Samija M ^c   Eljuga, D ^c   Turic M ^c   Harder, F ^a   Heberer, M ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; INTERLEUKIN 2; N(G) METHYLARGININE; NITRIC OXIDE; NITRITE; NITROPRUSSIDE SODIUM; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVITY; CELL CULTURE; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; METABOLIC INHIBITION; MONONUCLEAR CELL;

EID: 0030045220     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0261-5614(96)80255-X     Document Type: Review

References (38)

1. Barbul A, Lazarou S A, Efron D T, Wasserkrug H L, Efron G. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery 1990; 108: 331-337
2. Park K G M, Hayes P D, Garlick P J, Sewell H, Eremin O. Stimulation of lymphocyte natural cytotoxicity by L-arginine. Lancet 1991; 337: 645-646
3. Stuehr D J, Griffith O W. Mammalian nitric oxide synthases. Adv Enzymol Relat Areas Mol Biol 1992; 65: 287-346
4. Moncada S. The L-arginine: nitric oxide pathway. Acta Physiol Scand 1992; 145: 201-227
5. Marietta M A. Nitric oxide synthase structure and mechanism. J Biol Chem 1993; 268: 12231-12234
6. Lowenstein C J, Snyder S H. Nitric oxide, a novel biologic messenger. Cell 1992; 70: 705-707
7. Snyder S H, Bredt D S. Biological roles of nitric oxide. Sci Am 1992; 266: 28-35
8. Snyder S H. Nitric oxide: first in a new class of neurotransmitters. Science 1992; 257: 494-496
9. Moncada S, Higgs A. Mechanism of disease. N Engl J Med 1993; 329: 2002-2012
10. Hoffman R A, Langrehr J M, Billiar T R, Curran R D, Simmons R L. Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J Immunol 1990; 145: 2220-2226
11. Fu Y, Blankenhorn E P. Nitric oxide-induced anti-mitogenic effects in high and low responder rat strains. J Immunol 1992; 148: 2217-2222
12. Hibbs J B J, Taintor R R, Vavrin Z. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987; 235: 473-476
13. Stuehr D J, Nathan C F. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169: 1543-1555
14. Denham S, Rowland I J. Inhibition of the reactive proliferation of lymphocytes by activated macrophages: the role of nitric oxide. Clin exp Immunol 1992; 87: 157-162
15. Stein C S, Strejan G H. Rat splenocytes inhibit antigen-specific lymphocyte proliferation through a reactive nitrogen intermediate (RNI)-dependent mechanism and exhibit increased RNI production in response to INF-γ. Cell Immunol 1993; 150: 281-297
16. Nathan C F, Hibbs J B J. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 1991; 3: 65-70
17. Hoffman R A, Langrehr J M, Wren S M et al. Characterization of the immunosuppressive effects of nitric oxide in graft vs host disease. J Immunol 1993; 151: 1508-1518
18. Juretic A, Spagnoli G C, von Bremen K et al. Generation of lymphokine activated killer activity in rodents but not in humans is nitric oxide dependent. Cell Immunol 1994; 157: 462-477
19. Efron D T, Kirk S J, Regan M C, Wasserkrug H L, Barbul A. Nitric oxide generation from L-arginine is required for optimal human peripheral blood lymphocyte DNA synthesis. Surgery 1991; 110: 327-334
20. Palmer R M J, Rees D D, Ashton D S, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Comm 1988; 153: 1251-1256
21. Hibbs J B J, Vavrin Z, Taintor R R. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 1987; 138: 550-565
22. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilatation. J Clin Invest 1986; 78: 1-5
23. Juretic A, Spagnoli G C, Hörig H et al. Glutamine requirements in the generation of lymphokine-activated killer cells. Clin Nutr 1994; 13: 42-49
24. Juretic A, Knowles B B. SV40 T antigen acts as a minor histocompatibility antigen of SV40 T antigen in tolerant transgenic mice. Immunogenetics 1989; 29: 366-370
25. Ding A H, Nathan C F, Stuehr D J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence of independent production. J Immunol 1988; 141: 2407-2412
26. Hörig H, Spagnoli G C, Filgueira L et al. Exogenous glutamine requirement is confined to late events of T cell activation. J Cell Biochem 1993; 53: 343-351
27. Whiteside T L. Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations. In vivo 1991; 5: 553-560
28. Rosenberg S A. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10: 180-199
29. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993; 73: 5-8
30. Waldmann T A. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993; 14: 264-270
31. Archer S. Measurement of nitric oxide in biological models. FASEB J 1993; 7: 349-360
32. Hibbs J B J, Taintor R R, Vavrin Z, Granger D L. The role of macrophages as effector cells against tumors. In: Mitchell M S., ed. Biological approaches to cancer treatment: biomodulation, New York: McGraw-Hill, Inc. 1993: 27-54
33. Hibbs J B J, Westenfelder C, Taintor R et al. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 1992; 89: 867-877
34. Cameron M L, Granger D L, Weinberg J B, Kozumbo W J, Koren H L. Human alveolar and peritoneal macrophages mediate fungistasis independently of L-arginine oxidation to nitrite or nitrate. Am Rev Respir Dis 1990; 142: 1313-1319
35. Zembala M, Siedlar M, Marcinkiewicz J, Pryjma J. Human monocytes are stimulated for a nitric oxide release in vitro by some tumor cells but not by cytokines and lipopolysaccharide. Eur J Immunol 1994; 24: 435-439
36. Schneemann M, Schoedon G, Hofer S, Blau N, Guerrero L, Schaffner A. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J Infect Dis 1993; 167: 1358-1363
37. Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukocyte Biol 1991; 49: 380-387
38. De Maria R, Cifone M G, Trotta R et al. Triggering of human monocyte activation through CD69, a member of the natural killer gene complex family of signal transducing receptors. J Exp Med 1994; 180: 1999-2004